Supplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

• The analysis includes samples from baseline and on-treatment periods in different treatment arms, indicating comprehensive data collection.
• One patient in arm 2A and three patients in arm 2B did not undergo cystectomy, impacting treatment assessment.
• The focus is on biomarker dynamics related to ipilimumab and nivolumab in locally advanced urothelial cancer.
• The phase IB NABUCCO study highlights the interaction between treatment and biomarker changes.

Abstract